Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733284 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL12151911 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL12151378 | 0.91 | CYP3A4 (0.39) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL12151992 | 0.91 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL14883414 | 0.91 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL14883416 | 0.91 | CYP3A4 (0.46) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL12151904 | 0.89 | CYP2C19 (0.45) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL1733184 | 0.89 | CYP2C19 (0.45) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL12151954 | 0.89 | CYP2C19 (0.45) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL1733182 | 0.89 | CYP2C19 (0.45) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943221-B1 | PIPERAZINE AMIDINES AS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-23 | — | — | EP | disclosed |
| EP-1943221-A1 | PIPERAZINE AMIDINES AS ANTIVIRAL AGENTS | Brystol-Myers Squibb Company (US) | 2008-07-16 | — | — | EP | disclosed |
| US-7396830-B2 | Piperazine amidines as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| WO-2007041616-A1 | PIPERAZINE AMIDINES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078141-A1 | Piperazine amidines as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078141-A1 | Piperazine amidines as antiviral agents | IDO1, IDO2, EIF2AK2 | CYP3A4 644/4885CYP2C9 2045/4885CYP2C19 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.